Bipolar Depression Market Report 2032: Epidemiology Data, Pipeline Therapies, Latest FDA, EMA, PDMA Approvals by DelveInsight | Key Companies - AbbVie Inc., GlaxoSmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Brist

DelveInsight's "Bipolar Depression Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Bipolar Depression, historical and forecasted epidemiology as well as the Bipolar Depression market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Bipolar Depression market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Bipolar Depression Market Forecast
https://www.delveinsight.com/report-store/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Bipolar Depression Market Report:
• The Bipolar Depression market size is anticipated to grow with a significant CAGR during the study period (2019-2032)
• According to the National Institute of Mental Health (NIMH), a division of the National Institutes of Health (NIH), the 12-month prevalence of bipolar disorder among US individuals 18 and older was estimated to be 2.8% based on diagnostic interview data from the National Comorbidity Survey Replication (NCS-R). Additionally, it mentioned that 4.4% of US adults are thought to have bipolar disorder at some point in their lives
• The incidence of bipolar disorders across the globe is 2.4%, according to the French organization HAS, with equal prevalence in the United States, Europe, and Asia. According to estimates, bipolar disorder affects between 1% and 2.5% of people in France
• In the year 2021, there were 2,380.8 Thousand (K) diagnosed and treated cases of bipolar depression in the United States. It is predicted that this number would rise in the years to come.
• Key Bipolar Depression Companies: AbbVie Inc., GlaxoSmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• The number of cases of each type of bipolar depression in the US in 2021 was 934.9K for bipolar depression I and 1445.9K for bipolar depression II, respectively
• The Bipolar Depression market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Bipolar Depression pipeline products will significantly revolutionize the Bipolar Depression market dynamics.

Bipolar Depression Overview
A mental illness known as bipolar disorder (BD) is characterized by mood swings between mania and depression.
Bipolar disorder (BD) is primarily divided into BD-I, BD-II, cyclothymic disorder, and bipolar disorder not otherwise specified (NOS) based on the characteristics of the episodes.

Get a Free sample for the Bipolar Depression Market Report
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Bipolar Depression Epidemiology Segmentation:
The Bipolar Depression market report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:
• Total Prevalence of Bipolar Depression
• Prevalent Cases of Bipolar Depression by severity
• Gender-specific Prevalence of Bipolar Depression
• Diagnosed Cases of Episodic and Chronic Bipolar Depression

Download the report to understand which factors are driving Bipolar Depression epidemiology trends @ Bipolar Depression Epidemiology Forecast
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Bipolar Depression market or expected to get launched during the study period. The analysis covers Bipolar Depression market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market :
The report also covers the Bipolar Depression Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Bipolar Depression Therapies and Key Companies
• NRX-100/ NRX-101: NeuroRx
• SEP-4199: Sunovion (Sumitomo Dainippon Pharma)
• COMP 360 (Psilocybin Therapy): COMPASS Pathways
• Sage-217: SAGE Therapeutics
• cariprazine: Forest Laboratories
• Ketamine Hydrochloride: Target Health Inc.
• Lurasidone HCl: Vanguard, Inc.
• Quetiapine Fumarate (SEROQUEL): AstraZeneca
• Esketamine: Celon Pharma SA
• Lumateperone: Intra-Cellular Therapies, Inc.
• Brexpiprazole: Otsuka America Pharmaceutical
• OSU6162: Arvid Carlsson Research AB
• Bifeprunox: Solvay Pharmaceuticals
• carbamazepine ER: Shire
• ITI-007 (Lumateperone): Intra-Cellular Therapies, Inc.
• Olanzapine Fluoxetine Combination (OFC): Eli Lilly and Company
• lamotrigine: GlaxoSmithKline
• FK949E: Astellas Pharma Inc
• SM-13496: Sumitomo Pharma Co., Ltd.

Discover more about therapies set to grab major Bipolar Depression market share @ Bipolar Depression Treatment Market
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Bipolar Depression Market Drivers
• Future Directions in Blood Biomarkers
• Increase in Awareness and Technology
• Advances Toward Precision Medicine for Bipolar Depression

Bipolar Depression Market Barriers
• Misdiagnosis of Bipolar Depression
• Unsatisfactory Design of RCTs
• Limited Understanding of the Disease Mechanism

Scope of the Bipolar Depression Market Report
• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Bipolar Depression Companies AbbVie Inc., Glaxo SmithKline (GSK), ELI Lilly and Company, Janssen Pharmaceuticals, Astellas Pharma Inc., Bristol Myers Squibb, Gedeon Richter Plc., H. Lundbeck A/S, Pfizer Inc., Novartis AG, Otsuka Holdings Co. Ltd, Validus Pharmaceuticals LLC, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), COMPASS Pathways, SAGE Therapeutics, Forest Laboratories, Target Health Inc., Vanguard, Inc., AstraZeneca, Celon Pharma SA, Intra-Cellular Therapies, Inc., Arvid Carlsson Research AB, Solvay Pharmaceuticals, Shire, Intra-Cellular Therapies, Inc., and others
• Key Bipolar Depression Therapies: NRX-100, NRX-101, SEP-4199, COMP 360 (Psilocybin Therapy), Sage-217, cariprazine, Ketamine Hydrochloride, Lurasidone HCl, Quetiapine Fumarate (SEROQUEL), Esketamine, Lumateperone, Brexpiprazole, OSU6162, Bifeprunox, carbamazepine ER, ITI-007 (Lumateperone), Olanzapine Fluoxetine Combination (OFC), lamotrigine, FK949E, SM-13496, and others
• Bipolar Depression Therapeutic Assessment: Bipolar Depression current marketed and Bipolar Depression emerging therapies
• Bipolar Depression Market Dynamics: Bipolar Depression market drivers and Bipolar Depression market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Bipolar Depression Unmet Needs, KOL's views, Analyst's views, Bipolar Depression Market Access and Reimbursement

To know more about Bipolar Depression companies working in the treatment market, visit @ Bipolar Depression Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/bipolar-disorder-manic-depression-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Bipolar Depression Market Report Introduction
2. Executive Summary for Bipolar Depression
3. SWOT analysis of Bipolar Depression
4. Bipolar Depression Patient Share (%) Overview at a Glance
5. Bipolar Depression Market Overview at a Glance
6. Bipolar Depression Disease Background and Overview
7. Bipolar Depression Epidemiology and Patient Population
8. Country-Specific Patient Population of Bipolar Depression
9. Bipolar Depression Current Treatment and Medical Practices
10. Bipolar Depression Unmet Needs
11. Bipolar Depression Emerging Therapies
12. Bipolar Depression Market Outlook
13. Country-Wise Bipolar Depression Market Analysis (2019-2032)
14. Bipolar Depression Market Access and Reimbursement of Therapies
15. Bipolar Depression Market Drivers
16. Bipolar Depression Market Barriers
17. Bipolar Depression Appendix
18. Bipolar Depression Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:
Bipolar Depression Pipeline https://www.delveinsight.com/report-store/bipolar-depression-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"Bipolar Depression Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Bipolar Depression market. A detailed picture of the Bipolar Depression pipeline landscape is provided, which includes the disease overview and Bipolar Depression treatment guidelines.
Latest Reports by DelveInsight
Scedosporium Infection Market https://www.delveinsight.com/report-store/scedosporium-infection-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Scedosporium Infection Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Scedosporium Infection, historical and forecasted epidemiology as well as the Scedosporium Infection market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Vascular Graft Devices Market https://www.delveinsight.com/report-store/vascular-grafts-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Graft Devices Market By Product Type (Endovascular Grafts [Abdominal And Thoracic], Access Grafts, Peripheral Grafts, And Others), By Type (Knitted, Woven, And Others), By Material (Synthetic[ Polytetrafluoroethylene [PTFE], Polyester, Polyurethane], Biological, And Others), By End User (Hospitals, Ambulatory Surgical Centers, And Others), by geography is expected to register commendable revenue growth at a steady CAGR forecast till 2027 owing to increasing prevalence of cardiovascular diseases such as aortic aneurysms and peripheral artery disease and growing patient for kidney dialysis.

Vascular Stents Market https://www.delveinsight.com/report-store/vascular-stents-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Vascular Stents Market By Product Type (Coronary Stents, Peripheral Stents [Carotid Stents, Iliac Stents, Femoral Stents, Femoral Stents, Other], Evar Stent Grafts [Abdominal Aortic Aneurysm Stents, Thoracic Aortic Aneurysm Stents]), By Type (Bare-Metal Stents, Drug-Eluting Stents), By Material (Metal And Polymer), By Mode Of Delivery (Balloon-Expandable Stents And Self Expandable Stents), By End-User (Hospitals And Ambulatory Surgical Centers), by geography, is expected to grow at a noteworthy CAGR forecast till 2027 owing to rising burden of vascular diseases across the globe and increasing preferences of minimally invasive surgeries among the patient population.

Vein Illumination Devices Market https://www.delveinsight.com/report-store/vein-illumination-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Vein Illumination Devices Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Vein Illumination Devices and the historical and forecasted Vein Illumination Devices market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Bladder Scanners Market https://www.delveinsight.com/report-store/bladder-scanners-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Bladder Scanners Market Insight, Competitive Landscape and Market Forecast, 2027" report delivers an in-depth understanding of Bladder Scanners and the historical and forecasted Bladder Scanners market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Media Contact

Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.